Olubukola Ayodele: Honored to take part in the Urothelial Cancer preceptorship by ACE Oncology

Olubukola Ayodele shared a post on LinkedIn:

“It was truly an honor to have been chosen to take part in the Urothelial Cancer preceptorship in Madrid hosted by ACE Oncology.

It was an incredibly enlightening experience being under the guidance of Enrique Grande, the Director of the MD Anderson Cancer Center in Madrid.

We delved into recent updates from ESMO, such as the NIAGARA study, and discussed its potential impact on clinical practice.

We also explored the future of urothelial cancer and brainstormed on the best ways to potentially evolve clinical trials designs in various treatment settings.

We highlighted the challenges posed by the aggressive nature of urothelial cancers, emphasizing the significance of understanding the pathology and the need to tailor treatment to each individual patient.

I’m eager to see how the EVITA criteria can be utilized to assess the suitability of Enfortumab Vendotin (EV) in routine patient care.

Additionally, I had the privilege of touring the MD Anderson Cancer Center facilities in Madrid and visiting the Phase 1 unit to gain insights into their experiences and best practices.

Overall, I am deeply grateful for the wealth of knowledge gained and the valuable connections made with colleagues from around the world.”

Source: Olubukola Ayodele/LinkedIn

Olubukola Ayodele is a Consultant Medical Oncologist at the University Hospitals of Leicester NHS Trust, specializing in breast and genitourinary malignancies, including germ cell tumors. She is also an honorary Senior Lecturer at the University of Leicester and heads the Breast Cancer Clinical Trials Unit at the Leicester Cancer Research Centre. Dr. Ayodele’s work includes numerous publications, clinical trials, and collaborative research projects on molecular drivers and biomarkers in breast cancer. She is a member of ASCO, ESMO, ACP and UKBCG.